Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon.
about
Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patientsInterpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis CFuture of liver disease in the era of direct acting antivirals for the treatment of hepatitis CTreatment of hepatitis C. The 2002 French consensus.Occult hepatitis C: how convincing are the current data?Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment.Long-term viral negativity after interferon for chronic hepatitis C virus infection in hemodialysis.Treatment of chronic hepatitis C virus infection in patients with cirrhosis.Treatment of chronic hepatitis C virus infection.Treatment of chronic hepatitis C in haemophilia patients.Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up.Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis CLong-term effects of antiviral therapy in patients with chronic hepatitis C.Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirinInfrequent reinfection after successful treatment for hepatitis C virus infection in injection drug usersSerological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.Treatment of patients with HCV related cirrhosis: many rewards with very few risks.Development of hepatocellular carcinoma in patients with chronic hepatitis C more than 10 years after sustained virological response to interferon therapy.Sustained virological response: a milestone in the treatment of chronic hepatitis C.Basic answers to complicated questions for the course of chronic hepatitis C treatment.Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy.Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis.Post-treatment levels of α-fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C.Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis.α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2.Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index.Utility of real-time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis C infection without cirrhosis: Comparison of liver fibrosis indices.Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response.Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response.Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral.Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.First phase hepatitis c viral kinetics in previous nonresponders patients.Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon.
P2860
Q27489398-C2C6DFBC-59F0-499A-AA06-C9E4887887C9Q27490792-4949719B-80EC-4EC4-B260-3058411AB886Q30235178-BF8D77F2-BA91-4732-AD7A-EBF0F9BE4169Q33195269-875784F5-C7E2-4A09-9DC5-01349E7B1E5AQ33395436-D9FFDA7B-108D-4C5F-8432-8402B618E007Q33869545-2B3424C8-ABD3-4B69-9016-1F96C5042811Q33969758-85CD9385-B5E9-4F6C-97B5-95B68A151EC2Q34022678-08C080FF-1A6D-4213-B0CE-0B07AB91A96EQ34072137-6A11F9DF-E6D1-49E0-B2BA-E25BEB084827Q34107035-FF30FDF2-B3E2-430D-BCA4-1B2FD40C8487Q34125554-63D1B47C-5B22-4AC4-9F9A-01984620D3D2Q34172595-EFB37FF0-F9D5-4EF9-882D-62B6ED6B57EAQ34225573-EDD81BA9-C08A-4E1F-9AD3-986288485D85Q34415157-C7D5F710-4D3D-45B0-95B5-4BD6453694C2Q34521418-AC2E904D-489F-438A-961C-B6E01D2BE567Q34795057-00C947EC-18BB-4FFA-A32D-6567E6A7FF7AQ36052963-9379EF43-3AC3-42C6-A70B-04824836CD70Q36142732-98B7ACB6-4B7A-42B1-B275-A3BDFF20401CQ36216927-604CC432-6B1C-4716-AAA3-87C5CE6DB7D3Q36841325-25490417-38AD-4ABD-B533-604461B82186Q38014499-1EDBC7E8-48C9-4A06-B932-879F8413A382Q38758591-D555488F-AB62-44EB-8AA3-F9DE62CF5AE0Q38904167-53613760-5B89-4FD6-BFF5-34A59A89096AQ39564809-9ABFA275-BA65-4948-815D-F14B5487167EQ40361679-DEB0FA5F-5090-44AE-AB00-99A820D48A94Q40446411-30C3ED4C-D429-488F-8E2E-00865CA2AA06Q40469011-849760DA-263A-4EE0-A1C2-A6323CE4ED0BQ40557601-32367FB8-720D-4A02-BEFC-D5476FFD8873Q40695663-D949CC9A-1949-4841-98A4-4DE72481D405Q40791531-48F5A2B6-BA10-4FE2-9940-A5F0D74C00B3Q41013952-FA32CBF9-7559-4402-9741-F523D65883B0Q41549543-2F7D22C4-49F4-40EB-84D4-5613F4E2DC4FQ42229927-A56A19B2-B801-4C83-A145-8763F21CA7C4Q42287429-260B931E-FE3D-46AD-A772-DEA44819F894Q42580832-66BE6438-26BD-4EB4-9B8F-EC5A29561633Q42992092-D8701DA5-7B6C-4B82-B2D7-C583B491A5A2Q42992596-DEAE97AB-15B7-4F4C-931A-2233EBD832EFQ43037502-BD85015A-BC01-4F0A-9A17-710C764C887EQ43042198-1BA412FB-0146-4570-8777-38AF72C7C535Q43049453-73EA783C-9648-48AC-9326-AAA279FECB8B
P2860
Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Long-term follow-up of chronic ...... response to alpha-interferon.
@en
Long-term follow-up of chronic ...... response to alpha-interferon.
@nl
type
label
Long-term follow-up of chronic ...... response to alpha-interferon.
@en
Long-term follow-up of chronic ...... response to alpha-interferon.
@nl
prefLabel
Long-term follow-up of chronic ...... response to alpha-interferon.
@en
Long-term follow-up of chronic ...... response to alpha-interferon.
@nl
P2093
P1476
Long-term follow-up of chronic ...... response to alpha-interferon.
@en
P2093
P304
P356
10.1016/S0168-8278(99)80129-9
P50
P577
1999-05-01T00:00:00Z